Effects of intraocular dapiprazole in the rabbit eye

Bonomi, L.; Marchini, G.; Pagello, P.; Simonazzi, A.; Durando, L.; Ciarniello, M.G.

Journal of Cataract and Refractive Surgery 15(6): 681-684


ISSN/ISBN: 0886-3350
PMID: 2614713
DOI: 10.1016/s0886-3350(89)80037-9
Accession: 007277610

Download citation:  

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Dapiprazole produces miosis by blocking the alpha 1 receptors in the radial muscle of the iris; its intraocular effect has not yet been investigated. In this preliminary experimental animal study, we investigated the intracameral use of 0.2 ml of 0.005%, 0.0075%, 0.01%, and 0.05% dapiprazole to reverse mydriasis by 10% phenylephrine plus 0.5% tropicamide. With the 0.05% dapiprazole concentration, the values (mean .+-. S.E.) of pupillary diameter were as follows: prior to the experiment, 5.3 .+-. 0.31 mm; after mydriatics, 8.7 .+-. 0.22 mm; after intraocular dapiprazole, 5.6 mm .+-. 0.29. The results showed a dose-related miotic effect of dapiprazole. No difference in the toxicity parameters (inflammatory score, corneal thickness, endothelial cell counting, aqueous humor protein concentration, and intraocular pressure) was found between dapiprazoletreated eyes and saline-solution-treated eyes. Intraocular 0.01% and 0.05% dapiprazole is an effective miotic agent that may be helpful during surgery when the reversal of sympathomimetic mydriasis is needed.